Welcome to the TRIlogy-5 Study
A study for people whose multiple myeloma is not responding to their
current medication(s) or has returned after they’ve received
at least 1 to 3 prior lines of therapy.
Welcome to the TRIlogy-5 Study
A study for people whose multiple myeloma is not responding to their
current medication(s) or has returned after they’ve received
at least 1 to 3 prior lines of therapy.
The TRIlogy-5 Study is a Phase 3 study evaluating the safety and efficacy of an investigational medication in people whose multiple myeloma is not responding to their current medication(s) or has returned after they’ve received at least 1 to 3 prior lines of therapy. Participants in the study will receive either the investigational medication (Arm A) or a comparison medication (Arm B) for multiple myeloma.
Participants will be randomly assigned (like a flip of a coin) to 1 of the 2 study medication arms. Both you and the clinical staff will know which study medication you are receiving.
The goal of this study is to test how well the investigational medication works to stop or slow your multiple myeloma compared to a comparison medication.
Multiple myeloma is a type of cancer that starts in the bone marrow, where blood cells are made. It happens when certain cells called plasma cells grow out of control. These cells can hurt your bones, kidneys, and blood.
If you are in Arm A, you will receive the investigational medication. If you are in Arm B, you will receive a comparison medication until your disease worsens or you can no longer tolerate the side effects.
The investigational medication and comparison medication are given in 28-day cycles. You will need to visit the study clinic from 1 to 5 times per 28-day cycle.
About the Investigational Medication (Arm A)
The investigational medication is called a "trispecific antibody" and works by attaching to T cells (a type of white blood cell) and 2 different cancer cell proteins on multiple myeloma cells. The clinical significance of the mechanism of action (MoA) is not yet established.
Antibodies that normally occur in the body work by attaching to the proteins that are foreign to your body, such as those found on viruses or bacteria, to help stop an infection.
About the Comparison Medication (Arm B)
The comparison medication is called a “bispecific antibody." This medication works by attaching to proteins on T cells and to proteins on multiple myeloma cells.1
Both study medications are given as injections under the skin.
1Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of myeloma. Blood Cancer J. 2024;14(1)158. doi:10.1038/s41408-024-001139-y
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind: Even if you believe you meet the eligibility criteria, joining a clinical research study is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional.
Note about privacy: Email responses may not be encrypted. This means there’s a chance the messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.